We investigated the effect of reducing mitochondrial oxidative stress by the mitochondrial-targeted antioxidant peptide SS-31 in hypertensive cardiomyopathy.
Hypertension is a major global health issue, accounting for approximately one-half of the cases of stroke and ischemic heart disease and approximately 13% of total death worldwide (1) . Systemic hypertension induces left ventricular hypertrophy (LVH), fibrosis, and diastolic dysfunction and increases the risk of coronary artery disease, which leads to congestive heart failure (2) . The renin-angiotensin aldosterone system is the central regulator of hypertensive cardiovascular diseases. Angiotensin II (Ang) induces LVH, cardiac fibrosis, and diastolic dysfunction. At the molecular level, Ang binds to the angiotensin receptor-1 (ATR1), a guanine nucleotide-binding protein type q alpha subunit (G␣q)-coupled receptor, then stimulates nicotinamide adenine dinucleotide phosphate (NADPH) oxidases to produce reactive oxygen species (ROS) (3) . Recent studies have See page 83 reported that the nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) isoform of NADPH oxidase is present in mitochondria. The ROS generated by NADPH oxidase was shown to stimulate mitochondrial ROS production and induce mitochondrial dysfunction (4 -7) . Furthermore, we previously demonstrated that mitochondrial ROS plays a key role in aging and lifespan regulation, as
shown by approximately 20% extension of lifespan in mice overexpressing catalase targeted to mitochondria (mCAT) (8) . We further showed that mCAT attenuated age-dependent LVH and diastolic dysfunction, concomitant with attenuation of age-dependent increases in cardiac mitochondrial oxidative damage, without any effect on the increase of cardiac Ang observed in aged mice (9) . Therefore, we hypothesized that Ang might induce mitochondrial ROS in cardiomyocytes and that scavenging mitochondrial ROS by a mitochondrial-targeted antioxidant peptide might be beneficial in the setting of hypertensive cardiomyopathy.
The Szeto-Schiller (SS)-31 peptide (D-Arg-2=,6=-dimethyltyrosine-Lys-Phe-NH 2 ) belongs to a family of aromatic cationic peptides that selectively target to mitochondrial inner membrane and can scavenge superoxide, hydrogen peroxide, peroxynitrite, and hydroxyl radicals (10, 11) . The SS-31 has been shown to reduce mitochondrial ROS in epithelial, endothelial, and neuronal cells exposed to electron-transport-chain inhibitors as well as pro-oxidants including t-butylhydroperoxide and hypochlorous acid (12, 13) . The SS-31 also inhibits apoptosis mediated by mitochondrial release of cytochrome c elicited by mitochondrial permeability transition (11) . In vivo administration of SS-31 has demonstrated efficacy in several animal models associated with mitochondrial oxidative stress, including reduction of ischemia-reperfusion injury (14) , protection against neurodegeneration (15) , and prevention of insulin resistance induced by high-fat diet (16) . In this study, we demonstrated that Ang induced mitochondrial ROS in cardiomyocytes and increased cardiac mitochondrial protein oxidative damage. Reduction of mitochondrial ROS by SS-31 ameliorated Ang-induced cardiac hypertrophy, fibrosis, and apoptosis, concomitant with reduced activation of p38 mitogen-activated protein kinase (MAPK). The SS-31 administration also partially rescued the heart failure phenotype of mice with G␣q overexpression as a model of chronic catecholamine/Ang stimulation (17) .
Methods
Detailed methods are provided in the Online Appendix. Neonatal mouse cardiomyocytes were stimulated with Ang (1 mol/l), with or without simultaneous treatment of the following: SS-31 (1 nmol/l, kindly provided by Stealth Peptides, Inc., Newton Centre, Massachusetts), N-acetyl cysteine (NAC) (0.5 mmol/l), 4-chlorodiazepam (25 mol/l), diazoxide (200 mol/l), cyclosporine (0.5 mol/l), and/or 5-hydroxydecanoate (100 mol/l). Cardiomyocytes were then loaded with MitoSOX (5 mol/l) and CM-DCFDA (5 mol/l) to measure mitochondrial superoxide and total cellular ROS, respectively.
The FVBxC57BL/6J F1 hybrid mice (6 to 10/group, approximately 12 weeks of age) and wild-type littermates were treated with saline, Ang (1.1 mg/kg/day), Ang ϩ SS-31 (3 mg/kg/day), Ang ϩ NAC (approximately 500 mg/kg/day in drinking water) (18) , G␣q (FVBxC57BL/6 F2), or G␣q ϩSS-31 (3 mg/kg/day). Ang and SS-31 were continuously administered for 4 weeks with subcutaneous Alzet 1004 osmotic minipumps (Alzet, Cupertino, California). Echocardiography was performed at baseline and 4 weeks after pump. (Fig. 3A) , no change in LV end diastolic diameter (data not shown) or systolic function as measured by fractional shortening (FS) (Fig. 3B) , and an approximately 35% decline in Ea/Aa, an indicator of diastolic function (Fig. 3C) . Simultaneous administration of SS-31 significantly ameliorated Ang-induced cardiac hypertrophy and diastolic dysfunction, with a 33% reduction of LV mass index (Ang: 6.32 Ϯ 0.39 vs. Ang ϩ SS-31: 4.21 Ϯ 0.17 mg/g, p ϭ 0.001) (Fig. 3A, left panel) and better preservation of Ea/Aa (Ang: 0.723 Ϯ 0.15 vs. AngϩSS-31: 1.17 Ϯ 0.11, p ϭ 0.04) (Fig. 3C, left panel) . These effects 
were comparable to those of catalase targeted to mitochondria (inducible mCAT), in which induction of mitochondrial catalase 2 weeks before Ang also conferred protection against Ang-induced cardiac hypertrophy and diastolic dysfunction (Figs. 3A to 3D, right panels). To investigate whether the protective effect is specific to a mitochondrial targeted antioxidant, we administered the nontargeted antioxidant NAC in drinking water for 4 weeks simultaneously with the Ang pump. This treatment has been shown to ameliorate cardiomyopathy after acute aortic banding in mice (18); however, it did not show any beneficial effect on Ang-induced cardiomyopathy (Figs. 3A to 3C ). Ang increased heart weights by 45% above those of saline-treated control subjects (Fig. 4A ) (5.3 Ϯ 0.18 in saline vs. 7.69 Ϯ 0.20 in Ang, p Ͻ 0.001), and SS-31 protected heart weights (6.05 Ϯ 0.14 mg/mm, p Ͻ 0.01 vs. Ang alone), whereas oral NAC did not show any significant protection of heart weights (7.13 Ϯ 0.7 in Angϩ NAC vs. 7.69 Ϯ 0.20 in Ang, p ϭ 0.47). The cardiac hypertrophy phenotype was confirmed by qPCR for atrial natriuretic peptide, a fetal gene reactivated during hypertrophy. Ang induced an approximately 15-fold increased atrial natriuretic peptide gene expression, which was almost completely protected by SS-31, with no protection observed in the NAC-treated hearts (Fig. 4B) . Masson trichrome staining demonstrated perivascular fibrosis and interstitial fibrosis after Ang (Fig. 4C) . Ang significantly increased ventricular fibrosis, which was attenuated by SS-31 (Fig. 4D ). This was confirmed by qPCR of the procollagen 1a2 gene, the main component of cardiac fibrosis. As shown in Figure 4E , Ang-induced Coll1a2 gene expression was almost fully attenuated by SS-31. Oral NAC showed a nonsignificant reduction of ventricular fibrosis and Coll1a2 gene expression (Figs. 4D and 4E) . Ang-induced mitochondrial protein oxidative damage and signaling for mitochondrial biogenesis. Consistent with studies of ROS in cardiomyocytes (Fig. 1) , chronic administration of Ang for 4 weeks significantly increased The qPCR showed up-regulation of pro-collagen1a2 messenger ribonucleic acid (mRNA) after Ang, which was significantly reduced in SS-31 hearts but not in NAC hearts; n ϭ 4 to 7.
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Mitochondrial Antioxidant and Cardiomyopathy ventricular mitochondrial protein carbonyl content, an indicator of protein oxidative damage (p ϭ 0.03) (Fig. 5A ). This was significantly reduced by SS-31 (p ϭ 0.02) (Fig. 5A) , whereas nontargeted NAC did not show any significant reduction of mitochondrial protein oxidative damage (1.27 Ϯ 0.1 in Ang ϩ NAC vs. 1.44 Ϯ 0.1 in Ang, p ϭ 0.19) (Fig. 5A) . Peroxisome proliferator-activated receptor gamma coactivator (PGC-1␣) is known as a master regulator of mitochondrial biogenesis, regulating nuclear respiratory factors (NRFs) and mitochondrial transcription factor A, which transcribe nuclear deoxyribonucleic acid and mitochondrial deoxyribonucleic acid-encoded mitochondrial proteins, respectively (19) . Ang induced the expression of PGC-1␣ and its downstream target genes, including mitochondrial transcription factor A, NRF-1, and NRF-2 (Fig. 5B) . The SS-31 fully prevented this up-regulation of PGC-1␣ and target genes (p Ͻ 0.05 for all) (Fig. 5B) , whereas NAC did not show significant attenuation of any of these transcription factors. SS-31 attenuates Ang-induced up-regulation of NOX4 and reduces activation of p38 MAPK and apoptosis. Cardiac NOX4 protein expression was significantly increased in Ang-treated and G␣q overexpressing hearts (p ϭ 0.01) (Fig. 6A) , consistent with a recent report by Ago et al. (6) . The SS-31 significantly reduced NOX4 up-regulation in Ang-treated hearts (p ϭ 0.05) and trended toward reduction of NOX4 up-regulation in G␣q hearts (p ϭ 0.06) (Fig. 6A) , whereas NOX4 up-regulation was not attenuated by NAC (p ϭ 0.19) (Online Fig. 2A) .
Excessive mitochondrial ROS is well-known to induce apoptosis. Activated (cleaved) caspase 3, a marker of apoptosis, was increased in Ang-treated ventricular tissue (p ϭ 0.006), and this was almost completely attenuated by SS-31 (p ϭ 0.004) (Fig. 6C) . In contrast, NAC treatment did not reduce Ang-induced cleaved caspase-3 (Online Fig. 2B ). Ang treatment increased phosphorylation of p38 MAPK, and this was significantly attenuated by both SS-31 and NAC (Fig. 6B, Online Fig 2C) , suggesting that p38 phosphorylation depends on total ROS, regardless of the location in mitochondria or cytosol. SS-31 partially rescues G␣q overexpression-induced heart failure. To extend our observations to a model of chronic catecholamine/Ang stimulation, we applied the genetic mouse model of cardiac-specific overexpression of G␣q (a coupling protein to catecholamine and Ang receptors), which causes heart failure in mice by 14 to 16 weeks of age, despite the absence of increased BP (17) . We confirmed that G␣q mice had impaired systolic function at 16 weeks old, as shown by a substantial decline in FS (Fig. 7A) , with LV chamber enlargement (Fig. 7B) ; diastolic dysfunction, indicated by Ea/Aa Ͻ1 (Fig. 7C) ; and worsening of the myocardial performance index (Fig. 7D) . SS-31 administered from 12 to 16 weeks of age significantly reduced cardiac enlargement (p ϭ 0.001) (Fig. 7E) , ameliorated systolic function (p Ͻ 0.001 vs. untreated G␣q) (Fig. 7A) , and improved myocardial performance (p ϭ 0.04) (Fig. 7D ). There were trends toward amelioration of LV chamber enlargement (p ϭ 0.08) (Fig. 7B) and preservation of Ea/Aa (p ϭ 0.06) (Fig. 7C ) in SS-31-treated G␣q mice. There was a trend toward partial attenuation of increased lung weights by SS-31 (p ϭ 0.09) (Fig. 7E) . Ventricular fibrosis increased by approximately 2-fold in G␣q mice, which was not changed in SS-31-treated mice (Online Fig. 3A) , and this was confirmed by pro-collagen 1a2 qPCR (Online Fig. 3B ). Mitochondrial protein oxidative damage was evident in G␣q hearts (p ϭ 0.01) (Online Fig. 3C) , and SS-31-treated mice displayed significant reduction of cardiac mitochondrial protein carbonyls (p ϭ 0.05) (Online Fig. 3C ). There was no evidence of increased cleavedcaspase 3 in G␣q mouse hearts (data not shown).
Discussion
We found that mitochondrial ROS plays an essential role in hypertensive cardiomyopathies downstream of Ang and protection from mitochondrial ROS by a mitochondrialtargeted antioxidant confers resistance to cardiomyopathy, whereas nontargeted antioxidant NAC did not. Our study provides direct evidence that Ang induces mitochondrial The qPCR revealed significant up-regulation of genes in mitochondrial biogenesis, all of which were attenuated by SS-31. The NAC treatment did not significantly change any genes in mitochondrial biogenesis signaling. *p Ͻ 0.05 compared with saline group, #p Ͻ 0.05 compared with Ang-treated group, n ϭ 4 to 7. NRF ϭ nuclear respiratory factor; PGC-1␣ ϭ peroxisome proliferator-activated receptor gamma co-activator; TFAM ϭ transcription factor A; other abbreviations as in Figure 4 .
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ROS, which is prevented by SS-31 but not by NAC (Fig. 1) . We suggest that ROS amplified in mitochondria subsequently activates downstream ROS-sensitive signaling pathways implicated in pathological cardiac hypertrophy, including p38 MAPK (Fig. 6C) , apoptosis signal-regulating kinase (20) , other MAPKs (21), NF-B (22), and calcineurin-nuclear factor of activated T-cells (23) . Exposure to Ang for 4 weeks increased cardiac mitochondrial protein oxidative damage and induced the signaling for mitochondrial biogenesis (Fig. 5) , consistent with the previous report that hydrogen peroxide directly activates transcription of PGC-1␣, the master regulator of mitochondrial biogenesis (24) . SS-31 significantly attenuated Anginduced mitochondrial oxidative stress, reduced upregulation of mitochondrial biogenesis, and reduced ROSmediated p38 MAPK signaling (Fig. 8) . Because inhibition of p38 has been shown to improve cardiac remodeling and inflammation and preserve cardiac function in heart failure (25, 26) , the attenuation of Ang-induced p38 phosphorylation by SS-31 might be one of the downstream mechanisms underlying protection by SS-31. Furthermore, mitochondrial ROS can lead to apoptosis, and our results confirm that SS-31 prevented caspase-3 activation (Fig. 6) , concomitant with amelioration of Ang-induced cardiomyopathy (Figs. 3 and 4) .
It has been proposed that Ang mediates its effects via G␣q. However, G␣q transgenic overexpression involves a persistent lifelong stimulation of G␣q, starting from developmental stage, and is likely a stronger stimulus than obtained with Ang. Thus, transgenic overexpression of G␣q displayed a much stronger phenotype than 4-week Ang, including systolic heart failure in mice by 14 to 16 weeks of age (17) . The SS-31 for 4 weeks partially rescued the heart failure phenotype in mice overexpressing G␣q, including a significant amelioration of systolic dysfunction, cardiac hypertrophy, and myocardial performance (Figs. 7A, 7D, and 7E) .
Central to the scheme hypothesized in Figure 8 is the amplification of mitochondrial ROS, which can occur by multiple mechanisms. Ang is a key mediator of hypertension that binds to ATR1, a G␣q coupled-receptor, then activates NADPH oxidase through a protein kinase Protein levels of p38 MAPK also increased after Ang, n ϭ 3 to 6. GAPDH ϭ glyceraldehyde-3-phosphate dehydrogenase.
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Mitochondrial Antioxidant and Cardiomyopathy C-dependent mechanism. Although the NOX2 isoform of NADPH oxidase has been shown to mediate Ang effects, the NOX4 isoform has recently been reported to increase in response to various hypertrophic stimuli (6) and is localized in mitochondria (7), and activation of this isoform increases mitochondrial ROS (6) . Although our hypothesis indicates that ROS produced directly from NOX4 and/or indirectly by NOX2 isoform is amplified within mitochondria, the relative contribution of these isoforms in elevating ROS in mitochondria is not yet clear, and it is possible that NOX-independent mechanism(s) might also contribute to the Ang and G␣q phenotypes. Because escape of electrons from the mitochondrial electron transport complexes is a principal source of cellular ROS, oxidative damage to these complexes has been proposed to lead to a vicious cycle (27) . Another potential mechanisms of Ang-induced mitochondrial ROS could be the previously reported ROS-induced ROS release from mitochondria, which might be mediated by activation of the inner mitochondrial anion channel (inhibited by 4-chlorodiazepam) (28) , or the mitochondrial permeability transition pore (inhibited by cyclosporine) (29) , or mitochondrial K ATP channels (activated by diazoxide) (4) . The involvement of ROS-induced ROS release from mitochondria should be considered as a primary mechanism of Ang-induced ROS signaling (30) , as confirmed by observations that Ang-induced mitochondrial-ROS was reduced by simultaneous treatment with diazoxide, 4-chlorodiazepam, or cyclosporine A (Online Fig. 1 ). This places mitochondria in a central position for signal amplification and, conversely, for therapeutic targeting. Although most antihypertensive medications act upstream at the receptor level (beta-blockers, calcium channel blockers, angiotensin receptor blockers) or even at remote sites of action (diuretics, angiotensin-converting enzyme inhibitor), antioxidants provide an alternate intervention strategy in cardiac hypertrophy and failure. Several antioxidant studies have demonstrated some protective effect in cardiovascular diseases. For instance, Euk-8, a superoxide dismutase and catalase mimetic, ameliorated heart failure in ROS-sensitive mouse models subjected to pressure overload (31). Zhou et al. (32) reported that overexpression of metallothionein suppressed oxidative and nitrosative stress, apoptosis, and pathological remodeling in response to a short-term subpressor dose of Ang. Our study, however, points to the rationale of targeting antioxidants to mitochondria. The mitochondrial antioxidant MitoQ has been shown to reduce BP in the spontaneous hypertensive rat, concomitant with improvement of endothelial function and reduction of heart weight; however, the mechanism of cardioprotection was unclear (33). Our study found no effect of SS-31 on BP but showed evidence of direct cardioprotective mechanisms involv- (E) An increase in normalized heart weight in G␣q mice was substantially protected by SS-31, whereas there was a trend toward protection from increased normalized lung weight by SS-31 (p ϭ 0.09), n ϭ 3 to 6. LVEDD ϭ left ventricular end diastolic diameter; WT ϭ wild-type.
